On March 22, 2022, Chen, Yong; Zhuang, Xiaoxiao published a patent.Related Products of 16230-24-3 The title of the patent was Preparation of rociletinib as epidermal cell growth factor receptor mutation inhibitor. And the patent contained the following:
The present invention relates to preparation of rociletinib as epidermal cell growth factor receptor mutation inhibitor. In particular, the preparation method comprises of following steps; (a) substitution reaction between 1-[4-(4-amino-3-methoxyphenyl)piperazin-1-yl]ethan-1-one and di-tert-Bu dicarbonate under the action of a base and an organic solvent to obtain tert-Bu (4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)carbamate; (b) substitution reaction of step (a) product and 2,4-dichloro-5-(trifluoromethyl)pyrimidine under the action of a base and an organic solvent to obtain tert-Bu (4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)(4-chloro-5-(trifluoromethyl)pyrimidin-2-yl)carbamate; (c) substitution reaction of step (b) product and N-(3-aminophenyl)prop-2-enamide under the action of base and an organic solvent to obtain tert-Bu (4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)(4-((3-acrylamidophenyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)carbamate, and (d) hydrolysis reaction reaction of step (c) product under the action of an acid and an organic solvent to obtain the compound rociletinib. The preparation method of the epidermal cell growth factor receptor mutation inhibitor of the present invention has the advantages that the raw materials required for each step are cheap, easy to purchase, and the synthesis route is short, no isomers are produced, the intermediates are easy to sep. and purify, no column chromatog. is required, and the obtained product has high purity, high atom utilization, high yield, convenient purification, safe and simple reaction, and can be industrially produced. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).Related Products of 16230-24-3
The Article related to rociletinib preparation epidermal cell growth factor receptor mutation inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Related Products of 16230-24-3
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics